Milrinone Lactate

Milrinone Lactate

Milrinone Lactate Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Whether given orally or by continuous or intermittent intravenous infusion, milrinone has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure. In a multicenter trial of 1088 patients with Class III and IV heart failure, long-term oral treatment with milrinone was associated with no improvement in symptoms and an increased risk of hospitalization and death. In this study, patients with Class IV symptoms appeared to be at particular risk of life-threatening cardiovascular reactions. There is no evidence that milrinone given by long-term continuous or intermittent infusion does not carry a similar risk.

The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia. Long-term oral use has been associated with an increased risk of sudden death. Hence, patients receiving milrinone should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.


There is currently no drug history available for this drug.

Other Information

Milrinone Lactate Injection is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-Dihydro-2-methyl-6-oxo-[3,4´-bipyridine]-5-carbonitrile lactate and has the following structure:


Milrinone is an off-white to tan crystalline compound with a molecular weight of 211.22 and a molecular formula of C 12H9N3O. It is slightly soluble in methanol, and very slightly soluble in chloroform and in water. As the lactate salt, it is stable and colorless to pale yellow in solution. Milrinone Lactate Injection is available as a sterile aqueous solution of the lactate salt of milrinone for intravenous use.

Each mL of the 10 mL and 20 mL single dose vials contains milrinone lactate equivalent to 1 mg milrinone and 47 mg Dextrose, Anhydrous, USP in Water for Injection, USP. The pH is adjusted between 3.2 and 4.0 with lactic acid or sodium hydroxide. The total concentration of lactic acid can vary between 0.95 mg/mL and 1.29 mg/mL. These vials require preparation of dilutions prior to administration to patients intravenously.

Milrinone Lactate Manufacturers

  • Baxter Healthcare Corporation
    Milrinone Lactate (Milrinone Lactate) Injection, Solution [Baxter Healthcare Corporation]
  • West-ward Pharmaceutical Corp
    Milrinone Lactate Injection, Solution [West-ward Pharmaceutical Corp]
  • West-ward Pharmaceutical Corp
    Milrinone Lactate Injection, Solution [West-ward Pharmaceutical Corp]
  • West-ward Pharmaceutical Corp.
    Milrinone Lactate Injection [West-ward Pharmaceutical Corp.]
  • Hospira, Inc.
    Milrinone Lactate Injection, Solution [Hospira, Inc.]
  • App Pharmaceuticals, Llc
    Milrinone Lactate Injection, Solution [App Pharmaceuticals, Llc]
  • Bedford Laboratories
    Milrinone Lactate Injection [Bedford Laboratories]
  • Hospira, Inc.
    Milrinone Lactate Injection, Solution [Hospira, Inc.]

Login To Your Free Account